Bevacizumab: Current indications and future development for management of solid tumors

Expert Opinion on Biological Therapy

Volumn 9, Issue 4, 2009, Pages 507-517

  Jenab Wolcott, Jenia ^a   Giantonio, Bruce J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Advanced solid tumors; Angiogenesis; Bevacizumab; Chemotherapy; Metastatic; Targeted therapy; Vascular endothelial growth factor; VEGF

Indexed keywords

ALPHA2A INTERFERON; ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTERFERON; INTERLEUKIN 2; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLACEBO; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TEMOZOLOMIDE;

BLEEDING; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DEEP VEIN THROMBOSIS; DEMOGRAPHY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FISTULA; GLIOBLASTOMA; HUMAN; HYPERTENSION; IMMUNOTHERAPY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NOSE SEPTUM PERFORATION; OVARY CANCER; PERITONEUM CANCER; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROTEINURIA; REVIEW; SOLID TUMOR; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WOUND HEALING IMPAIRMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MANAGEMENT; HUMANS; NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67649298020     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590902817817     Document Type: Review

References (109)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-1186
2. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82(1):4-6
3. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6(4):389-395 (Pubitemid 30208155)
4. Fujimoto K, Hosotani R, Wada M, et al. Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer 1998;34(9):1439-1447 (Pubitemid 28370938)
5. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23(5):1011-1027 (Pubitemid 46202320)
6. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000;36(6):748-753 (Pubitemid 30179746)
7. Takahashi Y, Cleary KR, Mai M, et al. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 1996;2(10):1679-1684 (Pubitemid 26356351)
8. Takahashi Y, Kitadai Y, Bucana CD, et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55(18):3964-3968
9. Carmeliet P, Collen D. Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ann NY Acad Sci 2000;902:249-62; discussion 62-64
10. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20(21):4368-4380 (Pubitemid 35266299)
11. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669-676 (Pubitemid 36749215)
12. Beatty GL, Giantonio BJ. Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer. Expert Rev Anticancer Ther 2008;8(5):683-688
13. Midgley R, Kerr D. Bevacizumab-current status and future directions. Ann Oncol 2005;16(7):999-1004
14. Panares RL, Garcia AA. Bevacizumab in the management of solid tumors. Expert Rev Anticancer Ther 2007;7(4):433-445 (Pubitemid 46681799)
15. Borgstrom P, Gold DP, Hillan KJ, Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999;19(5B):4203-4214
16. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362(6423):841-844 (Pubitemid 23132159)
17. Melnyk O, Zimmerman M, Kim KJ, Shuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 1999;161(3):960-963 (Pubitemid 29422416)
18. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57(20):4593-4599 (Pubitemid 27441066)
19. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65(3):671-680 (Pubitemid 40216420)
20. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19(3):843-850 (Pubitemid 32119100)
21. Lin YS, Nguyen C, Mendoza JL, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999;288(1):371-378 (Pubitemid 29113511)
22. Hedrick E, Kozloff M, Hainsworth J, et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE). In: 2006 ASCO Annual Meeting; 2006: J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006:3536
23. VanCutsem E, Michael M, Berry S, et al. Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI, and capecitabine for mCRC: first BEATrial. 2007 Gastrointestinal Cancers Symposium (Abstract 346); 2007
24. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-2342 • A Phase III study comparing bevacizumab in addition to irinotecan, 5-fluorouracil and leucovorin (IFL) with IFL alone. (Pubitemid 38702844)
25. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21(1):60-65
26. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized Phase II trial. J Clin Oncol 2005;23(16):3697-3705 (Pubitemid 46252464)
27. Roche. Avastin Product Information. Nutley, NY: Roche; 2008
28. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005;69(Suppl 3):25-33 (Pubitemid 41680950)
29. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539-1544 • A Phase III study comparing bevacizumab plus FOLFOX with FOLFOX alone and bevacizumab alone. (Pubitemid 46733080)
30. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99(16):1232-1239 (Pubitemid 47299901)
31. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008;300(19):2277-2285
32. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22(11):2184-2191 (Pubitemid 41095154)
33. Badgwell BD, Camp ER, Feig B, et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 2008;19(3):577-582 (Pubitemid 351325682)
34. Giantonio BJ, Levy DE, O'Dwyer PJ, et al. A Phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 2006;17(9):1399-1403 (Pubitemid 44400378)
35. Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 2004;4(Suppl 2):S62-8 (Pubitemid 39440145)
36. Allegra CJ, Yothers G, O'Connell MJ, et al. Initial safety report of NSABP C-08, a randomized Phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer [abstract 4006]. 2008 ASCO annual meeting; J Clin Oncol 2008;26(May 20 Suppl)
37. Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 2007;105(1):3-6
38. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-434 • A Phase III study comarping placebo with bevacizumab 3 or 10 mg/kg every 2 weeks in metastatic renal cancer. (Pubitemid 36910021)
39. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007;25(30):4779-4786 (Pubitemid 350086481)
40. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 2008;26(4):689-690 (Pubitemid 351264373)
41. de Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997;33(2):214-219 (Pubitemid 27117717)
42. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15(2):808-815 (Pubitemid 27074252)
43. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J Clin Oncol 2008;26(12):2013-2019 • A Phase III trial involving use of bevacizumab in first line treatment of metastatic colorectal cancer.
44. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26(33):5326-5334 • A large observational study involving the use of bevacizumab in first line and second line treatment of metastatic colorectal cancer.
45. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized Phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007;25(29):4557-4561 (Pubitemid 350035312)
46. Hecht JR, Mitchell E, Chidiac T, et al. An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). 2008 Gastrointestinal Cancers Symposium (Abstract 273); 2008
47. Punt CJ, Tol J, Rodenburg CJ, et al. Randomized Phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) [abstract LBA4011]. 2008 ASCO Annual Meeting; J Clin Oncol 2008;26(May 20 Suppl)
48. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757-1765
49. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-2550 (Pubitemid 44917502)
50. Brahmer JR, Gray R, Schiller JH, et al. ECOG 4599 Phase III trial of carboplatin and paclitaxel ± bevacizumab: Subset analysis of survival by gender. In: 2006 ASCO Annual Meeting; 2006: J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006:7036
51. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26(1):60-65
52. Manegold C, von Pawel J, Zatloukal P, et al. Randomised, double-blind multicentre Phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 [abstract LBA7514]. 2007 ASCO Annual Meeting; 2007: J Clin Oncol 2007;25(18S) (June 20 Supplement)
53. Fu JB, Kau TY, Severson RK, Kalemkerian GP. Lung cancer in women: analysis of the national surveillance, epidemiology, and end results database. Chest 2005;127(3):768-777 (Pubitemid 40775504)
54. Pfister DG, Johnson DH, Azzoli CG, et al. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22(2):330-353
55. Schuette W. Treatment of brain metastases from lung cancer: chemotherapy. Lung Cancer 2004;45(Suppl 2):S253-7 (Pubitemid 39488196)
56. Velcheti V, Viswanathan A, Govindan R. The proportion of patients with metastatic non-small cell lung cancer potentially eligible for treatment with bevacizumab: a single institutional survey. J Thorac Oncol 2006;1(5):501 (Pubitemid 47181431)
57. Gridelli C, Maione P, Rossi A, De Marinis F. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments. Oncologist 2007;12(10):1183-1193 (Pubitemid 350106349)
58. Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005;23(8):1782-1790 (Pubitemid 46211430)
59. Traina TA, Rugo HS, Dickler M. Bevacizumab for advanced breast cancer. Hematol Oncol Clin North Am 2007;21(2):303-319 (Pubitemid 46754733)
60. Cobleigh MA, Langmuir VK, Sledge GW, et al. A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30(5 Suppl 16):117-124 (Pubitemid 37433402)
61. Miller KD, Chap LI, Holmes FA, et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-799 (Pubitemid 46224178)
62. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666- 2676
63. Miller KD. E2100: a Phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 2003;3(6):421-422
64. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2(11):1843-1849 (Pubitemid 26384151)
65. Klauber N, Parangi S, Flynn E, et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997;57(1):81-86 (Pubitemid 27021522)
66. Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, Phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO [abstract LBA1011]. J Clin Oncol 2008;26(May 20 Suppl)
67. Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 2007;25(20):2902-2908 (Pubitemid 47123154)
68. Han ES, Monk BJ. Bevacizumab in the treatment of ovarian cancer. Expert Rev Anticancer Ther 2007;7(10):1339-1345 (Pubitemid 351826900)
69. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 2008;5(4):194-204
70. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25(33):5165-5171 (Pubitemid 350237599)
71. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25(33):5180-5186 (Pubitemid 350232248)
72. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II consortia. J Clin Oncol 2008;26(1):76-82
73. Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 2007;13(4):1098-1106 (Pubitemid 46424048)
74. Hainsworth JD, Sosman JA, Spigel DR, et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005;23(31):7889-7896 (Pubitemid 46657387)
75. Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized Phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25(29):4536-4541 (Pubitemid 350035309)
76. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-2111 (Pubitemid 350296300)
77. Park YN, Kim YB, Yang KM, Park C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 2000;124(7):1061-1065 (Pubitemid 30602050)
78. Yamaguchi R, Yano H, Iemura A, et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998;28(1):68-77 (Pubitemid 28299987)
79. Pang R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 2006;242(2):151-167 (Pubitemid 44485315)
80. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004;41(5):864-880
81. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005;23(31):8093-8108 (Pubitemid 46657412)
82. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-390
83. Malka D, Dromain C, Farace F, et al. Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary results of a Phase II study with circulating endothelial cell (CEC) monitoring. In: 2007 ASCO Annual Meeting; 2007: J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007:4570
84. Schwartz JD, Schwartz M, Lehrer D, et al. Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. In: 2006 ASCO Annual Meeting; 2006: J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006:4144
85. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24(12):1898-1903 (Pubitemid 46638989)
86. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26(18):2992-2998
87. Lamszus K, Ulbricht U, Matschke J, et al. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res 2003;9(4):1399-1405 (Pubitemid 36418393)
88. Salmaggi A, Eoli M, Frigerio S, et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 2003;62(3):297-303 (Pubitemid 36591966)
89. Stefanik DF, Fellows WK, Rizkalla LR, et al. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J Neurooncol 2001;55(2):91-100 (Pubitemid 34065325)
90. Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 2008;112(10):2267-2273 (Pubitemid 351628638)
91. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13(4):1253-1259
92. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25(30):4722-4729
93. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23(31):8033-8040 (Pubitemid 46657405)
94. Seiwert TY, Haraf DJ, Cohen EE, et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol 2008;26(10):1732-1741
95. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment Phase II study of depot octreotide with bevacizumab and pegylated interferon alfa-2b. J Clin Oncol 2008;26(8):1316-1323
96. Wildiers H, Guetens G, De Boeck G, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003;88(12):1979-1986 (Pubitemid 36829677)
97. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10(2):145-147 (Pubitemid 38524883)
98. Giaccone G. The potential of antiangiogenic therapy in non-small cell lung cancer. Clin Cancer Res 2007;13(7):1961-1970 (Pubitemid 46649861)
99. Prat A, Casado E, Cortes J. New approaches in angiogenic targeting for colorectal cancer. World J Gastroenterol 2007;13(44):5857-5866 (Pubitemid 350148502)
100. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26(29):4714-4719
101. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006;24(35):5601-5608 (Pubitemid 46631341)
102. Rutkowski P, Debiec-Rychter M, Ruka W. Gastrointestinal stromal tumors: key to diagnosis and choice of therapy. Mol Diagn Ther 2008;12(3):131-143 (Pubitemid 351754587)
103. Rutkowski P, Symonides M, Zdzienicki M, Siedlecki JA. Developments in targeted therapy of advanced gastrointestinal stromal tumors. Rec Pat Anticancer Drug Discov 2008;3(2):88-99
104. Huang J, Frischer JS, Serur A, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003;100(13):7785-7790 (Pubitemid 36760047)
105. Rixe O, Verslype C, Khayat D, et al. A Phase I dose escalation (DE) and pharmacokinetics (PK) study of intravenous aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in patients with advanced solid tumors (STs) [abstract 3557]. In: 2008 ASCO Annual Meeting; 2008: J Clin Oncol 2008;26(May 20 Suppl)
106. Tang P, Cohen SJ, Bjarnason GA, et al. Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): A PMH phase II consortium trial [abstract 4027]. In: 2008 ASCO Annual Meeting; 2008: J Clin Oncol 2008;26(May 20 Suppl)
107. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9(4):1546-1556 (Pubitemid 36418413)
108. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62(16):4645-4655 (Pubitemid 34898591)
109. Natale RB. Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer. J Thorac Oncol 2008;3(6 Suppl 2):S128-30 (Pubitemid 351790696)